James L Boyer

List of Publications by Year in Descending Order

245 papers	10,964 citations	57 h-index	100 g-index
262 ext. papers	12,134 ext. citations	8.9 avg, IF	6.52 L-index

#	Paper	IF	Citations
245	Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis.. *JHEP Reports*, **2022**, 4, 100450	10.3	
244	The role of bile acids in cholestatic liver injury. *Annals of Translational Medicine*, **2021**, 9, 737	3.2	12
243	Role of Biliary Organoids in Cholestasis Research and Regenerative Medicine. *Seminars in Liver Disease*, **2021**, 41, 206-212	7.3	
242	The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiology. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 166085	6.9	3
241	Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. *Hepatology*, **2021**, 73, 2099-2109	11.2	18
240	Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis. *Journal of Hepatology*, **2021**, 74, 550-559	13.4	12
239	Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. *Hepatology Communications*, **2021**, 5, 2035-2051	6	0
238	A homozygous R148W mutation in Semaphorin 7A causes progressive familial intrahepatic cholestasis. *EMBO Molecular Medicine*, **2021**, 13, e14563	12	0
237	Letter to the Editor: On the Mechanisms of Biliary Flux. *Hepatology*, **2021**,	11.2	
236	Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. *Clinical Pharmacology and Therapeutics*, **2020**, 108, 1213-1223	6.1	7
235	Polyploidy in Liver Function, Mitochondrial Metabolism, and Cancer **2020**, 603-613		
234	miRNAs and Hepatocellular Carcinoma **2020**, 183-194		
233	Bile Acid Metabolism in Health and Disease **2020**, 269-285		1
232	Cholangiocyte Biology and Pathobiology **2020**, 391-407		
231	-Antitrypsin Deficiency **2020**, 645-658		0
230	Pathophysiology of Portal Hypertension **2020**, 659-669		1
229	Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis **2020**, 821-850		1

228	Pluripotent Stem Cells and Reprogramming **2020**, 1036-1042		
227	A Positive Feedback Loop of TET3 and TGF-β1 Promotes Liver Fibrosis. *Cell Reports*, **2020**, 30, 1310-1318.e5	10.6	22
226	The Central Role of the Liver in Iron Storage and Regulation of Systemic Iron Homeostasis **2020**, 215-228		
225	Time for the Elimination of Hepatitis C Virus as a Global Health Threat **2020**, 935-952		1
224	The Dual Role of ABC Transporters in Drug Metabolism and Resistance to Chemotherapy **2020**, 1007-1014		0
223	Gap and Tight Junctions in Liver **2020**, 160-173		
222	Disorders of Bilirubin Metabolism **2020**, 229-244		1
221	Primary Biliary Cholangitis: 2018 Practice Guidance From the American Association for the Study of Liver Diseases. *Clinical Liver Disease*, **2020**, 15, 1-2	2.2	6
220	Molecular Cholestasis **2020**, 351-363		1
219	Basolateral Plasma Membrane Organic Anion Transporters **2020**, 327-336		1
218	Telomeres and Telomerase in Liver Generation and Cirrhosis **2020**, 992-999		
217	Ribosome Biogenesis and its Role in Cell Growth and Proliferation in the Liver **2020**, 174-182		
216	Copper Metabolism and the Liver **2020**, 207-214		
215	Hepatic Adenosine Triphosphate-Binding Cassette Transport Proteins and Their Role in Physiology **2020**, 313-326		1
214	Polycystic Liver Diseases **2020**, 408-421		0
213	Ca2+ Signaling in the Liver **2020**, 496-508		
212	Clinical Genomics of NAFLD **2020**, 509-520		1
211	Developmental Morphogens and Adult Liver Repair **2020**, 539-549		0

210	Drug-Induced Liver Injury **2020**, 701-713	3
209	Toll-like Receptors in Liver Disease **2020**, 737-746	1
208	Experimental Models of Liver Cancer **2020**, 747-757	
207	Treatment of Liver Cancer **2020**, 782-791	
206	Hepatitis E Virus **2020**, 915-925	
205	Biological Principles and Clinical Issues Underlying Liver Transplantation for Viral-Induced End-Stage Liver Disease in the Era of Highly Effective Direct-Acting Antiviral Agents **2020**, 926-934	
204	Chromatin Regulation and Transcription Factor Cooperation in Liver Cells **2020**, 1043-1049	
203	Drug Interactions in the Liver **2020**, 1050-1057	1
202	Metabolic Regulation of Hepatic Growth **2020**, 1058-1061	
201	Nuclear Pore Complex **2020**, 94-107	0
200	Mutations and Genomic Alterations in Liver Cancer **2020**, 773-781	
199	Catenin Signaling **2020**, 585-602	
198	Stem Cell-Fueled Maturational Lineages in Hepatic and Pancreatic Organogenesis **2020**, 521-538	
197	Peroxisome Assembly, Degradation, and Disease **2020**, 137-150	
196	Embryonic Development of the Liver **2020**, 14-22	1
195	Pathophysiologic Basis for Alternative Therapies for Cholestasis **2020**, 364-377	1
194	Liver Regeneration **2020**, 566-584	8
193	Liver-Directed Gene Therapy **2020**, 979-991	1

192	Liver Repopulation by Cell Transplantation and the Role of Stem Cells in Liver Biology **2020**, 550-565	1
191	Clinical Implications of the Molecular Biology of Hepatitis B Virus **2020**, 851-867	
190	Oxidative Stress and Inflammation in the Liver **2020**, 714-727	4
189	Imaging Cellular Proteins and Structures **2020**, 965-978	
188	Molecular Biology of Hepatitis Viruses **2020**, 793-820	0
187	Lineage Tracing **2020**, 1069-1074	
186	Lipoprotein Metabolism and Cholesterol Balance **2020**, 255-267	2
185	Organizational Principles of the Liver **2020**, 1-13	3
184	Hepatocyte Apoptosis **2020**, 195-205	1
183	Hepatic Lipid Droplets in Liver Function and Disease **2020**, 245-254	
182	Cytoskeletal Motors **2020**, 23-35	
181	Stellate Cells and Fibrosis **2020**, 444-454	0
180	Non-alcoholic Fatty Liver Disease and Insulin Resistance **2020**, 455-471	4
179	The Kidney in Liver Disease **2020**, 630-644	1
178	Non-alcoholic Fatty Liver Disease **2020**, 670-681	1
177	Viral Escape Mechanisms in Hepatitis C and the Clinical Consequences of Persistent Infection **2020**, 868-888	
176	Integrated Technologies for Liver Tissue Engineering **2020**, 1028-1035	
175	Hepatic Nuclear Receptors **2020**, 337-350	0

174	The Liver Sinusoidal Endothelial Cell **2020**, 422-434	6
173	The Hepatocellular Secretory Pathway **2020**, 75-85	
172	TGR5 (GPBAR1) in the Liver **2020**, 286-298	
171	Bile Acids as Signaling Molecules **2020**, 299-312	2
170	AMPK **2020**, 472-484	2
169	Insulin-Mediated PI3K and AKT Signaling **2020**, 485-495	2
168	The Hepatocyte as a Household for Plasmodium Parasites **2020**, 1075-1080	1
167	Endocytosis in Liver Function and Pathology **2020**, 62-74	1
166	Fenestrations in the Liver Sinusoidal Endothelial Cell **2020**, 435-443	5
165	The Gut Microbiome and Liver Disease **2020**, 1062-1068	0
164	Primary Cilia **2020**, 50-61	
163	Genome Editing by Targeted Nucleases and the CRISPR/Cas Revolution **2020**, 953-964	1
162	Toxins and Biliary Atresia **2020**, 1000-1006	0
161	Nucleoside Antiviral Agents for HCV **2020**, 906-914	
160	Mitochondrial Function, Dynamics, and Quality Control **2020**, 86-93	
159	Hepatocyte Surface Polarity **2020**, 36-49	0
158	Stem Cell-Derived Liver Cells **2020**, 1015-1021	
157	Organelle Organelle Contacts **2020**, 151-159	

156	Inflammasome Is Activated in the Liver of Cholestatic Patients and Aggravates Hepatic Injury in Bile Duct-Ligated Mouse. *Cellular and Molecular Gastroenterology and Hepatology*, **2020**, 9, 679-688	7.9	17
155	Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital Diarrhea. *Hepatology*, **2020**, 71, 1879-1882	11.2	10
154	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 179-187.e6	6.9	24
153	Protein Maturation and Processing at the Endoplasmic Reticulum **2020**, 108-121		1
152	Protein Degradation and the Lysosomal System **2020**, 122-136		1
151	Epidemiology of Hepatocellular Carcinoma **2020**, 758-772		19
150	Tracking Hepatitis C Virus Interactions with the Hepatic Lipid Metabolism **2020**, 889-905		1
149	Extracellular Vesicles and Exosomes **2020**, 1022-1027		3
148	Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies. *Methods in Molecular Biology*, **2019**, 1981, 363-372	1.4	5
147	Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology*, **2019**, 69, 394-419	11.2	224
146	Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. *Hepatology*, **2019**, 70, 871-882	11.2	25
145	Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. *Liver International*, **2018**, 38, 1128-1138	7.9	25
144	Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 591-593	6.9	10
143	Histologic features of autoimmune hepatitis: a critical appraisal. *Human Pathology*, **2018**, 82, 51-60	3.7	19
142	H19 Is Expressed in Hybrid Hepatocyte Nuclear Factor 4 Periportal Hepatocytes but Not Cytokeratin 19 Cholangiocytes in Cholestatic Livers. *Hepatology Communications*, **2018**, 2, 1356-1368	6	8
141	Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. *Gastroenterology*, **2018**, 155, 1578-1592.e16	13.3	17
140	The Role of Inflammation in the Mechanisms of Bile Acid-Induced Liver Damage. *Digestive Diseases*, **2017**, 35, 232-234	3.2	17
139	Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study. *Journal of Clinical Gastroenterology*, **2017**, 51, e11-e16	3	29

138	Na-taurocholate cotransporting polypeptide (NTCP/SLC10A1) ortholog in the marine skate is not a physiological bile salt transporter. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2017**, 312, R477-R484	3.2	2
137	Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response. *JCI Insight*, **2017**, 2, e90780	9.9	131
136	CFTR-associated ligand is a negative regulator of Mrp2 expression. *American Journal of Physiology - Cell Physiology*, **2017**, 312, C40-C46	5.4	1
135	Mechanisms of bile acid mediated inflammation in the liver. *Molecular Aspects of Medicine*, **2017**, 56, 45-53	16.7	105
134	Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury. *Inflammation and Cell Signaling*, **2017**, 4,		4
133	Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. *Hepatology*, **2016**, 64, 2151-2164	11.2	36
132	A Novel Di-Leucine Motif at the N-Terminus of Human Organic Solute Transporter Beta Is Essential for Protein Association and Membrane Localization. *PLoS ONE*, **2016**, 11, e0158269	3.7	8
131	Treatment of chronic cholestasis: What we know and what we will know?. *Clinical Liver Disease*, **2016**, 8, 140-144	2.2	
130	A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients. *Digestive Diseases and Sciences*, **2016**, 61, 3506-3512	4	20
129	Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. *Science*, **2015**, 347, 1253-6	33.3	190
128	Fibrates and cholestasis. *Hepatology*, **2015**, 62, 635-43	11.2	148
127	Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. *Journal of Hepatology*, **2015**, 63, 1440-8	13.4	33
126	Na(+) /H(+) exchanger regulatory factor 1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury. *Hepatology*, **2015**, 62, 1227-36	11.2	13
125	Altered expression and function of canalicular transporters during early development of cholestatic liver injury in Abcb4-deficient mice. *American Journal of Physiology - Renal Physiology*, **2014**, 306, G670-6	5.1	14
124	The role of macrophage migration inhibitory factor in autoimmune liver disease. *Hepatology*, **2014**, 59, 580-91	11.2	75
123	All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice. *Journal of Pharmacology and Experimental Therapeutics*, **2014**, 349, 94-8	4.7	27
122	Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations. *Molecular Aspects of Medicine*, **2014**, 37, 3-14	16.7	43
121	Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice. *Journal of Hepatology*, **2014**, 60, 160-6	13.4	37

120	Peroxisome proliferator-activated receptor □activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. *Hepatology*, **2014**, 59, 1030-42	11.2	53
119	Bile formation and secretion. *Comprehensive Physiology*, **2013**, 3, 1035-78	7.7	428
118	Now you see it, now you don₱. *Hepatology*, **2013**, 58, 446-447	11.2	4
117	Adult sea lamprey tolerates biliary atresia by altering bile salt composition and renal excretion. *Hepatology*, **2013**, 57, 2418-26	11.2	21
116	Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. *Hepatology*, **2012**, 55, 1485-94	11.2	58
115	A C-terminal tyrosine-based motif in the bile salt export pump directs clathrin-dependent endocytosis. *Hepatology*, **2012**, 55, 1901-11	11.2	25
114	Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. *American Journal of Physiology - Renal Physiology*, **2012**, 302, G925-36	5.1	43
113	Small-duct sclerosing cholangitis associated with Schistosoma mansoni. *Hepatology*, **2011**, 53, 712-3	11.2	1
112	Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. *Hepatology*, **2011**, 53, 548-57	11.2	82
111	Drug-induced cholestasis. *Hepatology*, **2011**, 53, 1377-87	11.2	236
110	Ost□depletion protects liver from oral bile acid load. *American Journal of Physiology - Renal Physiology*, **2011**, 301, G574-9	5.1	18
109	NHERF-1 binds to Mrp2 and regulates hepatic Mrp2 expression and function. *Journal of Biological Chemistry*, **2010**, 285, 19299-307	5.4	46
108	Role of breast cancer resistance protein in the adaptive response to cholestasis. *Drug Metabolism and Disposition*, **2010**, 38, 1673-8	4	32
107	Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. *Journal of Lipid Research*, **2010**, 51, 2265-74	6.3	63
106	Aryl hydrocarbon receptor and NF-E2-related factor 2 are key regulators of human MRP4 expression. *American Journal of Physiology - Renal Physiology*, **2010**, 299, G126-35	5.1	69
105	Organic solute transporter, OSTalpha-OSTbeta: its role in bile acid transport and cholestasis. *Seminars in Liver Disease*, **2010**, 30, 178-85	7.3	47
104	Cholestasis: genetic and acquired. *Seminars in Liver Disease*, **2010**, 30, 113-5	7.3	2
103	The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. *Seminars in Liver Disease*, **2010**, 30, 125-33	7.3	78

102	Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. *Hepatology*, **2010**, 51, 181-90	11.2	57
101	OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids. *Frontiers in Bioscience - Landmark*, **2009**, 14, 2829-44	2.8	80
100	It's all about bile. *Hepatology*, **2009**, 49, 711-23	11.2	10
99	Nuclear factor erythroid 2-related factor 2 is a positive regulator of human bile salt export pump expression. *Hepatology*, **2009**, 50, 1588-96	11.2	60
98	ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. *Gastroenterology*, **2009**, 136, 1060-9	13.3	81
97	Bile canalicular secretion - tales from Vienna and Yale. *Wiener Medizinische Wochenschrift*, **2008**, 158, 534-8	2.9	6
96	N-Glycosylation of the alpha subunit does not influence trafficking or functional activity of the human organic solute transporter alpha/beta. *BMC Cell Biology*, **2008**, 9, 57		16
95	Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. *Hepatology*, **2008**, 48, 1558-69	11.2	61
94	Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis. *FASEB Journal*, **2008**, 22, 796.1	0.9	
93	Ultrastructural Evidence of Intrahepatic Cholestasis Before and After Chenodeoxycholic Acid Therapy in Patients with Cholelithiasis: The National Cooperative Gallstone Study. *Hepatology*, **2007**, 3, 209-220	11.2	31
92	Nuclear receptors RXRalpha:RARalpha are repressors for human MRP3 expression. *American Journal of Physiology - Renal Physiology*, **2007**, 292, G1221-7	5.1	25
91	Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. *American Journal of Physiology - Cell Physiology*, **2007**, 293, C1709-16	5.4	81
90	The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2007**, 293, R1400-9	3.2	33
89	New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. *Journal of Hepatology*, **2007**, 46, 365-71	13.4	63
88	Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis. *Hepatology*, **2006**, 43, 1013-21	11.2	147
87	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. *American Journal of Physiology - Renal Physiology*, **2006**, 290, G1124-30	5.1	218
86	FXR: a target for cholestatic syndromes?. *Expert Opinion on Therapeutic Targets*, **2006**, 10, 409-21	6.4	37
85	Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct-ligated rats. *Drug Metabolism and Disposition*, **2006**, 34, 1301-9	4	15

84	Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. *Gastroenterology*, **2006**, 131, 878-84	13.3	89
83	A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. *World Journal of Gastroenterology*, **2006**, 12, 2536-48	5.6	7
82	Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?. *Gastroenterology*, **2005**, 129, 735-40	13.3	62
81	Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. *Hepatology*, **2005**, 42, 1184-93	11.2	94
80	OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. *Hepatology*, **2005**, 42, 1270-9	11.2	277
79	Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis. *Hepatology*, **2004**, 39, 1382-9	11.2	57
78	Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters. *American Journal of Physiology - Renal Physiology*, **2004**, 286, G762-8	5.1	12
77	Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat. *Journal of Hepatology*, **2004**, 40, 585-91	13.4	151
76	Mechanisms of Bile Formation: An Introduction **2004**, 1-8		1
75	Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. *Journal of Biological Chemistry*, **2003**, 278, 17810-8	5.4	65
74	Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. *Journal of Biological Chemistry*, **2003**, 278, 27473-82	5.4	144
73	Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. *Journal of Biological Chemistry*, **2003**, 278, 36688-98	5.4	124
72	Cholestatic syndromes. *Current Opinion in Gastroenterology*, **2003**, 19, 216-31	3	8
71	Bile salt transporters: molecular characterization, function, and regulation. *Physiological Reviews*, **2003**, 83, 633-71	47.9	775
70	Down-regulation of the Na+/taurocholate cotransporting polypeptide during pregnancy in the rat. *Journal of Hepatology*, **2003**, 38, 148-55	13.4	36
69	Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. *Hepatology*, **2002**, 36, 49-54	11.2	60
68	Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. *Seminars in Liver Disease*, **2002**, 22, 123-36	7.3	97
67	Cholestatic syndromes. *Current Opinion in Gastroenterology*, **2002**, 18, 314-29	3	6

66	Unimpaired osmotic water permeability and fluid secretion in bile duct epithelia of AQP1 null mice. *American Journal of Physiology - Renal Physiology*, **2002**, 283, G739-46	5.1	33
65	Sperber I. Secretion of organic anions in the formation of urine and bile[Pharmacol. Rev. 1959;11:109-134]. *Journal of Hepatology*, **2002**, 36, 4-7	13.4	6
64	Organ-specific alterations in RAR alpha:RXR alpha abundance regulate rat Mrp2 (Abcc2) expression in obstructive cholestasis. *Gastroenterology*, **2002**, 123, 599-607	13.3	68
63	The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. *Journal of Clinical Investigation*, **2002**, 110, 965-972	15.9	107
62	The role of bile salt export pump mutations in progressive familial intrahepatic cholestasis type II. *Journal of Clinical Investigation*, **2002**, 110, 965-72	15.9	32
61	Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver. *Hepatology*, **2001**, 33, 783-91	11.2	229
60	Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat. *Gastroenterology*, **2001**, 121, 1473-84	13.3	136
59	Role of sodium/hydrogen exchanger isoform NHE3 in fluid secretion and absorption in mouse and rat cholangiocytes. *American Journal of Physiology - Renal Physiology*, **2001**, 280, G247-54	5.1	49
58	Cl(-)-dependent secretory mechanisms in isolated rat bile duct epithelial units. *American Journal of Physiology - Renal Physiology*, **2001**, 281, G438-46	5.1	18
57	Isolation of functional polarized bile duct units from mouse liver. *American Journal of Physiology - Renal Physiology*, **2001**, 280, G241-6	5.1	21
56	Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. *American Journal of Physiology - Renal Physiology*, **2001**, 281, G316-22	5.1	51
55	Induction of murine hepatocyte death by membrane-bound CD95 (Fas/APO-1)-ligand: characterization of an in vitro system. *Hepatology*, **2000**, 32, 779-85	11.2	24
54	Bile salt excretion in skate liver is mediated by a functional analog of Bsep/Spgp, the bile salt export pump. *American Journal of Physiology - Renal Physiology*, **2000**, 278, G57-63	5.1	23
53	ATP-dependent GSH and glutathione S-conjugate transport in skate liver: role of an Mrp functional homologue. *American Journal of Physiology - Renal Physiology*, **2000**, 279, G417-25	5.1	23
52	Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. *Seminars in Liver Disease*, **2000**, 20, 373-84	7.3	95
51	Molecular identification and functional characterization of Mdr1a in rat cholangiocytes. *Gastroenterology*, **2000**, 119, 1113-22	13.3	40
50	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. *Gastroenterology*, **2000**, 118, 163-72	13.3	222
49	Canalicular export pumps traffic with polymeric immunoglobulin A receptor on the same microtubule-associated vesicle in rat liver. *Journal of Biological Chemistry*, **1999**, 274, 26416-24	5.4	35

48	Hepatic sequestration and modulation of the canalicular transport of the organic cation, daunorubicin, in the Rat. *Hepatology*, **1999**, 29, 483-93	11.2	21
47	Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes. *Hepatology*, **1999**, 29, 477-82	11.2	70
46	The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. *Hepatology*, **1999**, 30, 602-5	11.2	19
45	Molecular regulation of hepatocellular transport systems in cholestasis. *Journal of Hepatology*, **1999**, 31, 165-78	13.4	131
44	Characterization of ion transport mechanisms involved in bombesin-stimulated biliary secretion in rat cholangiocytes. *Journal of Hepatology*, **1999**, 30, 1045-51	13.4	19
43	Vasoactive intestinal polypeptide is a potent regulator of bile secretion from rat cholangiocytes. *Gastroenterology*, **1999**, 117, 420-8	13.3	58
42	Clinicopathology conferences: inflammation-induced cholestasis. *Hepatology*, **1998**, 28, 253-60	11.2	57
41	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na+/taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. *Hepatology*, **1998**, 28, 789-95	11.2	21
40	Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. *Hepatology*, **1998**, 28, 1449-53	11.2	182
39	Nitric oxide and guanosine 3',5'cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. *Hepatology*, **1998**, 28, 1621-8	11.2	24
38	Molecular pathogenesis of cholestasis. *New England Journal of Medicine*, **1998**, 339, 1217-27	59.2	645
37	Enterohepatic circulation of scymnol sulfate in an elasmobranch, the little skate (Raja erinacea). *American Journal of Physiology - Renal Physiology*, **1997**, 273, G1023-30	5.1	10
36	ATP regulation of a swelling-activated osmolyte channel in skate hepatocytes. *The Journal of Experimental Zoology*, **1997**, 279, 471-5		11
35	Regulation of intracellular pH in the hepatocyte. Mechanisms and physiological implications. *Journal of Hepatology*, **1996**, 24, 631-44	13.4	33
34	Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets. *Gastroenterology*, **1995**, 109, 1600-11	13.3	94
33	Cytoskeletal organization in clusters of isolated polarized skate hepatocytes: structural and functional evidence for microtubule-dependent transcytosis. *The Journal of Experimental Zoology*, **1995**, 271, 273-84		15
32	Effects of protein kinase C and cytosolic Ca2+ on exocytosis in the isolated perfused rat liver. *Hepatology*, **1994**, 20, 1032-40	11.2	33
31	Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. *Journal of Hepatology*, **1994**, 20, 707-13	13.4	126

30	Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes. *Gastroenterology*, **1993**, 104, 604-12	13.3	103
29	Effects of Ca2+ agonists on cytosolic Ca2+ in isolated hepatocytes and on bile secretion in the isolated perfused rat liver. *Hepatology*, **1992**, 15, 107-16	11.2	67
28	Papaverine inhibits transcytotic vesicle transport and lipid excretion into bile in isolated perfused rat liver. *Hepatology*, **1992**, 16, 1036-42	11.2	13
27	Mechanisms and regulation of bile secretion. *Hepatology*, **1991**, 14, 551-566	11.2	352
26	Mechanisms and regulation of bile secretion **1991**, 14, 551		27
25	Taurocholate stimulates transcytotic vesicular pathways labeled by horseradish peroxidase in the isolated perfused rat liver. *Gastroenterology*, **1990**, 99, 216-28	13.3	91
24	Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. *Methods in Enzymology*, **1990**, 192, 534-45	1.7	57
23	Cryptic Na+,K(+)-ATPase activity in rat liver canalicular plasma membranes: evidence for its basolateral origin. *Hepatology*, **1990**, 11, 223-9	11.2	18
22	The use of isolated rat hepatocyte couplets in hepatobiliary physiology. *Journal of Hepatology*, **1990**, 10, 387-94	13.4	44
21	Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. *Methods in Enzymology*, **1990**, 192, 517-33	1.7	25
20	Hepatic toxicity of vitamin A and synthetic retinoids. *Journal of Gastroenterology and Hepatology (Australia)*, **1990**, 5, 334-42	4	56
19	Protein kinase C agonists inhibit bile secretion independently of effects on the microcirculation in the isolated perfused rat liver. *Hepatology*, **1989**, 10, 8-13	11.2	59
18	The effect of changes in the fluid state of rat liver plasma membrane on the transport of taurocholate. *Hepatology*, **1987**, 7, 61-6	11.2	53
17	Isolated rat hepatocyte couplets in short-term culture: structural characteristics and plasma membrane reorganization. *Hepatology*, **1987**, 7, 216-23	11.2	142
16	Mechanisms of Bile Secretion and Hepatic Transport **1986**, 609-636		26
15	Effect of albumin binding on extraction of sulfobromophthalein by perfused elasmobranch liver: evidence for dissociation-limited uptake. *Hepatology*, **1984**, 4, 492-501	11.2	51
14	Primary biliary cirrhosis. *Hepatology*, **1984**, 4, 29S-32S	11.2	15
13	Biochemical separation of Na+,K+-ATPase from a "purified" light density, "canalicular"-enriched plasma membrane fraction from rat liver. *Hepatology*, **1983**, 3, 18-28	11.2	44

12	Tight junctions in normal and cholestatic liver: does the paracellular pathway have functional significance?. *Hepatology*, **1983**, 3, 614-7	11.2	66
11	The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. *New England Journal of Medicine*, **1983**, 308, 1-7	59.2	360
10	A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. *Hepatology*, **1982**, 2, 187-201	11.2	42
9	Structural heterogeneity of hepatocyte "tight" junctions: a quantitative analysis. *Hepatology*, **1981**, 1, 193-203	11.2	26
8	Sodium taurocholate modifies the bile acid-independent fraction of canalicular bile flow in the rhesus monkey. *Journal of Clinical Investigation*, **1979**, 64, 312-20	15.9	42
7	Selective Hepatic Uptake and Biliary Excretion of 35S-Sulfobromophthalein in Marine Elasmobranchs. *Gastroenterology*, **1976**, 70, 254-256	13.3	15
6	Canalicular bile secretion in man. Studies utilizing the biliary clearance of (14C)mannitol. *Journal of Clinical Investigation*, **1974**, 54, 773-81	15.9	108
5	Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis). *New England Journal of Medicine*, **1970**, 283, 1063-71	59.2	216
4	Canalicular Bile flow and Bile Secretory Pressure. *Gastroenterology*, **1970**, 59, 853-859	13.3	100
3	Hepatic metabolism of 1-14C octanoic and 1-14C margaric acids. *Lipids*, **1969**, 4, 615-7	1.6	5
2	Thiobacillus novellus. I. Growth on organic and inorganic media. *Journal of Bacteriology*, **1959**, 78, 197-202	3.5	30
1	Adaptive Regulation of Hepatocyte Transporters in Cholestasis681-702		1